Cell News and Research

RSS

Broken motors induce stress and anxiety in mice

When motors break down, getting where you want to go becomes a struggle. Problems arise in much the same way for critical brain receptors when the molecular motors they depend on fail to operate. Now, researchers reporting in Cell Reports, a Cell Press publication, on February 7, have shown these broken motors induce stress and anxiety in mice. The discovery may point the way to new kinds of drugs to treat anxiety and other disorders.

10 Feb 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Drugs that target retromer pathway could help prevent or treat Parkinson's

Columbia University Medical Center (CUMC) researchers have identified a protein trafficking defect within brain cells that may underlie common non-familial forms of Parkinson's disease.

9 Feb 2013

CtBP may play a key role in aggressive forms of breast cancer

A protein associated with conditions of metabolic imbalance, such as diabetes and obesity, may play a role in the development of aggressive forms of breast cancer, according to new findings by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues.

9 Feb 2013

Scientists create nanoscale vehicle to battle cancer without harming healthy cells

A tiny capsule invented at a UCLA lab could go a long way toward improving cancer treatment. Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells.

9 Feb 2013

TIC10 may improve usefulness of TRAIL protein in cancer therapy

A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

9 Feb 2013

Intravitreal ranibizumab shows little benefit after hemorrhage

Ranibizumab given intravitreally offers no clear benefit in the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy, a randomized clinical trial indicates.

8 Feb 2013

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

Researchers have found that circulating levels of tumor necrosis factor receptor 2 are independently associated with the development of chronic kidney disease in nonobese Japanese patients with Type 2 diabetes.

8 Feb 2013

Milk thistle constituent shows promising skin protection properties

Silibinin, a key component of milk thistle seeds, can help protect against skin damage caused by ultraviolet B radiation, show study findings published in Molecular Carcinogenesis.

8 Feb 2013

Oral eosinophilic ulcers ‘a self-limiting, reactive condition’

A review of patients with oral eosinophilic ulcers suggests that the lesions should be considered a reactive, local condition rather than a CD30+ lymphoproliferative disorder.

8 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

On the fourth floor of Wichita State University's McKinley Hall, biochemistry professor Kandatege Wimalasena and his group of doctoral and undergraduate students are hard at work researching Parkinson's disease (PD) - the second-most common neurodegenerative disease, affecting 1 to 2 percent of people older than 60.

7 Feb 2013

Key details of how TRF2 protein performs crucial chromosome-protecting function

We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.

7 Feb 2013

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

7 Feb 2013

Basis of antidepressant drugs and electroconvulsive therapy found

Through a series of investigations in mice and humans, Johns Hopkins researchers have identified a protein that appears to be the target of both antidepressant drugs and electroconvulsive therapy. Results of their experiments explain how these therapies likely work to relieve depression by stimulating stem cells in the brain to grow and mature.

7 Feb 2013

Glimmer of hope for imatinib-resistant GIST

The monoclonal antibody SR1 can significantly inhibit gastrointestinal stromal tumor cell growth, report researchers in the Proceedings of the National Academy of Sciences.

7 Feb 2013

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences, Inc. today reported fourth quarter and full year 2012 financial results and accomplishments.

7 Feb 2013

ACL injuries on the rise among young athletes

Until a child's bones have fully matured (in girls, typically by age 14; in boys, age 16), an injury to the anterior cruciate ligament (ACL)-the primary, stabilizing ligament of the knee joint-requires special consideration, treatment and care to ensure appropriate healing and to prevent long-term complications.

7 Feb 2013

New method can determine seriousness of cancer prognosis with 80% certainty

The number of incorrect cancer prognoses can be halved with computerised image analysis. In three years time, the method can be used on patients with bowel cancer, ovarian cancer and prostate cancer.

6 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013